FDA Says Gilead Issues Voluntary Nationwide Recall Of One Lot Of Veklury For Injection 100 mg/Vial Due To The Presence Of A Glass Particle
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences, Inc. has issued a voluntary recall of one lot of Veklury (remdesivir) for Injection 100 mg/vial due to the presence of a glass particle. This recall is a precautionary measure as no adverse events have been reported. Veklury is used for treating COVID-19 in certain patients.
September 23, 2024 | 4:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Gilead Sciences has recalled a lot of Veklury due to glass particles. This could impact investor confidence, but no adverse events have been reported, which may mitigate negative effects.
The recall of a pharmaceutical product due to contamination can negatively impact investor confidence and potentially affect stock prices. However, the lack of reported adverse events may limit the negative impact. The recall is a precautionary measure, which shows Gilead's commitment to safety, possibly mitigating some investor concerns.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100